Overview
As colorectal cancer (CRC) research advances globally, generating robust real-world evidence specific to Japanese patients remains critical to understanding treatment patterns and optimizing care. This study used the Japan Flatiron Health Research Database to examine patient characteristics, biomarker testing practices, and treatment patterns in a cohort of over 3,000 CRC patients.
Researchers found that biomarker testing rates were high (>80%) across all key standard-of-care biomarkers, with mutation patterns consistent with prior reports—including higher KRAS positivity in right-sided versus left-sided disease, identifiable using information abstracted from unstructured data sources in the EHR. Among patients with metastatic disease, >90% received first-line systemic therapy, with treatment patterns in subcohorts defined by biomarker status and tumor sidedness being treated with a combination of regimens aligned with clinical expectations.
Why this matters
This comprehensive real-world study reveals important variability in how Japanese CRC patients are characterized and treated. These findings provide valuable insights that can help identify opportunities to optimize care pathways, inform treatment decision-making, and guide future research priorities specific to the Japanese population—ultimately advancing the evidence base for improved patient outcomes.